NCT02787863View on ClinicalTrials.gov

Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology

PHASE4CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

September 6, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Chronic Obstructive Pulmonary DiseaseAsthmaPneumococcal Infections
Interventions
BIOLOGICAL

Prevenar-13

Conjugate 13 serotype pneumococcal vaccine

BIOLOGICAL

Pneumo-23

Polysaccharide 23-valent pneumococcal vaccine.

Trial Locations (2)

105064

Institute of Sera and Vaccines RAS, Moscow

443099

Samara State Medical Univercity, Samara

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Mikhael Petrovich Kostinov

OTHER

NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology | Biotech Hunter | Biotech Hunter